BR112022008580A2 - Métodos para tratar transtornos depressivos - Google Patents

Métodos para tratar transtornos depressivos

Info

Publication number
BR112022008580A2
BR112022008580A2 BR112022008580A BR112022008580A BR112022008580A2 BR 112022008580 A2 BR112022008580 A2 BR 112022008580A2 BR 112022008580 A BR112022008580 A BR 112022008580A BR 112022008580 A BR112022008580 A BR 112022008580A BR 112022008580 A2 BR112022008580 A2 BR 112022008580A2
Authority
BR
Brazil
Prior art keywords
methods
depressive disorders
treat depressive
human
compound
Prior art date
Application number
BR112022008580A
Other languages
English (en)
Inventor
Louise Harden Cynthia
N Beatch Gregory
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of BR112022008580A2 publication Critical patent/BR112022008580A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MÉTODOS PARA TRATAR TRANSTORNOS DEPRESSIVOS. Em certas modalidades, a presente invenção é direcionada a métodos para tratar transtornos depressivos em um humano, em que os métodos compreendem administrar oralmente uma quantidade terapeuticamente eficaz de N-[4-(6-fluoro-3,4-di-hidro-1H-isoquinolin-2-il)-2,6-dimetilfenil]-3,3-dimetilbutanamida (Composto A), ao humano em necessidade do mesmo. A presente invenção é adicionalmente direcionada a vários métodos melhorados de terapia e administração do Composto A.
BR112022008580A 2019-11-08 2020-11-06 Métodos para tratar transtornos depressivos BR112022008580A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932724P 2019-11-08 2019-11-08
PCT/US2020/059481 WO2021092439A1 (en) 2019-11-08 2020-11-06 Methods of treating depressive disorders

Publications (1)

Publication Number Publication Date
BR112022008580A2 true BR112022008580A2 (pt) 2022-08-09

Family

ID=73643360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008580A BR112022008580A2 (pt) 2019-11-08 2020-11-06 Métodos para tratar transtornos depressivos

Country Status (17)

Country Link
US (1) US20210161886A1 (pt)
EP (1) EP4054580A1 (pt)
JP (1) JP2022553569A (pt)
KR (1) KR20220098746A (pt)
CN (1) CN114667146A (pt)
AU (1) AU2020380961A1 (pt)
BR (1) BR112022008580A2 (pt)
CA (1) CA3155812A1 (pt)
CL (1) CL2022001102A1 (pt)
CO (1) CO2022008001A2 (pt)
CR (1) CR20220250A (pt)
IL (1) IL292678A (pt)
MA (1) MA56607A1 (pt)
MX (1) MX2022005490A (pt)
PE (1) PE20221766A1 (pt)
TW (1) TW202128162A (pt)
WO (1) WO2021092439A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3207191A1 (en) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia
US20220288057A1 (en) * 2021-02-09 2022-09-15 Xenon Pharmaceuticals Inc. Conjoint therapy for treating seizure disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2420960T3 (es) * 2006-08-23 2013-08-28 Valeant Pharmaceuticals International Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
US8993593B2 (en) 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators

Also Published As

Publication number Publication date
AU2020380961A1 (en) 2022-05-26
CR20220250A (es) 2022-08-19
WO2021092439A1 (en) 2021-05-14
MX2022005490A (es) 2022-08-10
US20210161886A1 (en) 2021-06-03
PE20221766A1 (es) 2022-11-11
CO2022008001A2 (es) 2022-06-10
TW202128162A (zh) 2021-08-01
IL292678A (en) 2022-07-01
CA3155812A1 (en) 2021-05-14
EP4054580A1 (en) 2022-09-14
KR20220098746A (ko) 2022-07-12
MA56607A1 (fr) 2022-10-31
CL2022001102A1 (es) 2023-01-27
CN114667146A (zh) 2022-06-24
JP2022553569A (ja) 2022-12-23

Similar Documents

Publication Publication Date Title
BR112023015527A2 (pt) Inibidores de cdk e métodos de uso destes
BR112019005930A2 (pt) combinações compreendendo um inibidor de ssao/vap-1 e um inibidor de sglt2, e usos das mesmas
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112022008580A2 (pt) Métodos para tratar transtornos depressivos
EA201591610A1 (ru) Ингибиторы кинуренинового пути
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
PH12020551898A1 (en) Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
BR112021021826A2 (pt) Terapias de combinação compreendendo os inibidores de apremilast e tyk2
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
MX2022010357A (es) Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina.
BR112016013734A2 (pt) Composto, composição farmacêutica, kit, e uso de um composto
BR112022010733A2 (pt) Métodos para tratar dor
BR112022016360A2 (pt) Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
BR112021017314A2 (pt) Uso de extrato de elaeocarpus sylvestris
BR112023023030A2 (pt) Composições e métodos para o tratamento de depressão
BR112023017367A2 (pt) Composições e métodos para inibição de ceto-hexoquinase (khk)
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
BR112015023806A2 (pt) Novos regimes de dosagem de celgosivir para o tratamento de dengue
BR112022005881A2 (pt) Compostos de benzoxazinona como inibidores duplos de klk5/7
CO2023011948A2 (es) Terapia conjunta para el tratamiento de trastornos convulsivos
CL2021002846A1 (es) Terapias de combinación que comprenden inhibidores de apremilast y tyk2
BR112022010540A2 (pt) Métodos para tratar sintomas comportamentais e psicológicos em pacientes com demência
MX2022006630A (es) Uso de reboxetina para tratar los trastornos del sistema nervioso.